China News Service, Xi'an, September 5 (Reporter Zhang Yichen and Mei Yilong) Recently, a 550,000 yuan hospital fee receipt from the Second Affiliated Hospital of Xi'an Jiaotong University has attracted attention online.

According to the bill, a young girl was hospitalized for 4 days starting from August 17 this year, and the cost of western medicine was RMB 550,000.

　　Among them, the western medicine fee of 550,000 was questioned by netizens, and the reporter contacted the Second Affiliated Hospital of Xi'an Jiaotong University in response to this matter.

The staff of the hospital told reporters that two months ago, Xiaohua (anonymous), who was less than 2 years old, came to the Children’s Hospital of the Second Affiliated Hospital of Xi’an Jiaotong University because of weakness in limbs and backward movement.

The neurological expert team of the Children's Hospital conducted a genetic diagnosis of Xiaohua, and finally diagnosed as spinal muscular atrophy (SMA).

　　According to Huang Shaoping, a professor at the Children’s Hospital of the Second Affiliated Hospital of Xi’an Jiaotong University, SMA is a rare disease in which muscle weakness and muscle atrophy are caused by degeneration of the motor neurons in the anterior horn of the spinal cord.

The incidence is about one in 10,000.

In May 2018, the disease was included in the "List of the First Batch of Rare Diseases" jointly formulated by the National Health Commission and other departments. It is the second-ranked neuromuscular rare disease.

Children with onset in infancy have a high probability of not living to 2 years old.

　　Faced with the confirmed Xiaohua, the neurological professional team of the Children's Hospital of the hospital formulated a detailed treatment plan for Xiaohua.

According to Xiaohua’s clinical manifestations and genetic examination results, and according to the "Clinical Practice Guidelines for Spinal Muscular Atrophy" published by the Chinese Medical Association Genetic Diseases Clinical Practice Guidelines Writing Group, Xiaohua has no contraindications to drug use, so after communicating with her family, And signed an informed consent to treat Xiaohua with Noxinagen sodium.

　　It is understood that the noxinagen sodium used by Xiaohua in children is the world's first precise targeted treatment of SMA. By increasing the level of SMN protein in patients with SMA, it can change the course of the disease and improve the prognosis.

According to the reporter's inquiry, the current domestic price of the drug is about 500,000 yuan.

　　The staff of the hospital told reporters that the waves caused by the incident on the Internet have caused great psychological pressure on the families of the children.

At the same time, the family members of the children were very dissatisfied with the behavior of the online bills exposing the child's hospital number and family members' signatures, and the behavior has affected their normal life.

　　In addition, the staff member showed the reporter a text message from the family of the child. The text read, “My child’s spinal muscular atrophy needs to be treated with the imported drug Noxinarine Sodium, which I agree with. Of." (End)